Valeant Pharma (VRX) option implied volatility elevated into Q1 and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Valeant Pharma (VRX) Reports Q1 Revenues Above Estimates; Boosts FY18 Revenue & EBITDA Outlook
May 8, 2018 7:05 AM EDTValeant Pharma (NYSE: VRX) reported Q1 EPS of ($7.68), versus $0.60 reported last year. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.95 billion.
Outperformed Expectations in the First Quarter of 2018Revenues of $1.995 BillionGAAP Net Loss of $2.693 BillionGAAP Cash Flow from... More